Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study

Modern Rheumatology
Tsutomu TakeuchiRaj Tummala

Abstract

To evaluate the safety of sifalimumab in Japanese patients with systemic lupus erythematosus (SLE). This phase 2, open-label study consisted of a 52-week initial stage (Stage I) and a long-term extension (Stage II). In Stage I, sequential cohorts of patients received ascending doses of sifalimumab (intravenous [IV] 1.0, 3.0, and 10.0 mg/kg or subcutaneous 100 mg every 2 weeks; IV 600 and 1200 mg every 6 weeks). In Stage II, patients enrolled before June 2012 received the same dose of sifalimumab as during Stage I for up to 157 weeks or sifalimumab 600 mg IV every 4 weeks if they enrolled later. The safety of sifalimumab was assessed by adverse events (AEs). Thirty patients enrolled in Stage I and 21 patients entered Stage II. The majority of patients experienced AEs (96.7% in Stage I and 100% in Stage II); most were mild or moderate in severity. Serious AEs occurred in 30.0% and 57.1% of patients in Stage I and II, respectively; most were instances of SLE flares. The proportion of patients in Stage I and II who had AEs leading to discontinuation was 10.0% and 28.6%, respectively. Sifalimumab was well tolerated in Japanese patients with SLE.

References

Sep 1, 1993·Current Opinion in Rheumatology·M C Hochberg, M Petri
Feb 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emily C BaechlerTimothy W Behrens
Mar 19, 2003·The Journal of Experimental Medicine·Lynda BennettVirginia Pascual
Sep 18, 2003·Arthritis and Rheumatism·Mary K Crow
Dec 14, 2004·Arthritis and Rheumatism·Kyriakos A KirouMary K Crow
Jul 27, 2006·Arthritis and Rheumatism·S BernatskyR Ramsey-Goldman
Aug 7, 2007·Best Practice & Research. Clinical Rheumatology·Michelle Petri
Mar 29, 2008·Lupus·A Doria, C Briani
Mar 15, 2011·Journal of the American Academy of Dermatology·Rachel KleinVictoria P Werth
Jan 25, 2012·Rheumatology·Guillermo Ruiz-IrastorzaMunther Khamashta
Jun 3, 2014·Lancet·Larissa LisnevskaiaDavid Isenberg
Jun 28, 2018·Modern Rheumatology·Kenji Oku, Tatsuya Atsumi

❮ Previous
Next ❯

Citations

Jul 24, 2020·Expert Opinion on Investigational Drugs·Jacqueline L Paredes, Timothy B Niewold
Dec 18, 2020·Current Opinion in Rheumatology·Antonios G A KoliosGeorge C Tsokos
Oct 31, 2020·Frontiers in Immunology·Bingyi YangQianjin Lu
Apr 20, 2021·Frontiers in Pediatrics·Debora M d'AngeloFrancesco Chiarelli
Jul 3, 2021·International Journal of Molecular Sciences·Giulia Di DonatoFrancesco Chiarelli
Dec 25, 2021·Rheumatology·Michel W P Tsang-A-Sjoe, Irene E M Bultink

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.